title: PPARγ ligand attenuates portal inflammation in the MRL-lpr mouse: a new strategy to restrain cholangiopathy in primary biliary cirrhosis.
abstract: Primary biliary cirrhosis (PBC) is characterized by chronic destructive cholangitis, which is associated with the reduced expression of an anti-inflammatory molecule, peroxisome proliferator-activated receptor-γ (PPARγ), in intrahepatic bile ducts. We previously demonstrated the anti-inflammatory effects of PPARγ ligands using cultured human biliary epithelial cells. In this study, we evaluated the effectiveness of PPARγ ligand against peribiliary inflammation in vivo. As an animal model of PBC, we used MRL/lpr mice in which a PBC-like cholangitis occurs naturally. Anti-inflammatory effects of the intraperitoneal administration of a PPARγ ligand, the prostaglandin D metabolite 15-deoxy-Δ(12,14)-prostaglandin J2 (15d-PGJ2), were evaluated. In untreated mice, portal inflammation including cholangitis was found to some degree in the majority of portal tracts. In mice given a high-dose group, the degree of portal inflammation was significantly reduced and mice mostly lacking portal inflammation and cholangitis were also found. T cell numbers in portal tracts were markedly decreased in the high-dose group, compared with controls, whereas there was no significant difference in terms of B cells and macrophages. This study is the first to assess the therapeutic potential of a PPARγ ligand against portal inflammation including cholangitis. Anti-inflammatory effects of PPARγ ligands may prevent the progression of cholangiopathy in PBC patients.
authors: Department of Human Pathology, Kanazawa University Graduate School of Medicine, Kanazawa, 920-8640, Japan.
authors: Yusuke
authors: Y
authors: Nozaki
authors: Kenichi
authors: K
authors: Harada
authors: Takahiro
authors: T
authors: Sanzen
authors: Yasuni
authors: Y
authors: Nakanuma
mesh_terms: D000818:Animals; D002761:Cholangitis / Q000188:drug therapy* / Q000276:immunology; D004353:Drug Evaluation, Preclinical; D005260:Female; D006801:Humans; D008102:Liver Circulation; D008105:Liver Cirrhosis, Biliary / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D047495:PPAR gamma / Q000819:agonists* / Q000378:metabolism; D011168:Portal System / Q000187:drug effects / Q000276:immunology*; D015230:Prostaglandin D2 / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: C477819:15-deoxyprostaglandin J2; D047495:PPAR gamma; D015230:Prostaglandin D2
references: Trends Mol Med. 2001 Aug;7(8):329-31
references: 11516972
references: J Clin Invest. 1999 Aug;104(4):383-9
references: 10449430
references: J Exp Med. 1995 May 1;181(5):1835-45
references: 7536796
references: J Endocrinol. 1999 Sep;162(3):331-40
references: 10467224
references: Cell. 1995 Dec 1;83(5):813-9
references: 8521498
references: J Clin Pathol. 2006 Feb;59(2):184-90
references: 16443736
references: Dis Markers. 2010;29(6):287-99
references: 21297248
references: Int Rev Immunol. 2000;19(4-5):473-98
references: 11016428
references: Am J Gastroenterol. 2002 Jan;97(1):209-10
references: 11808957
references: J Immunol. 2012 May 1;188(9):4568-80
references: 22467656
references: Pathol Int. 2001 Jun;51(6):418-24
references: 11422802
references: Proc Natl Acad Sci U S A. 2010 May 11;107(19):8772-7
references: 20421464
references: J Hepatol. 2000 Jul;33(1):9-18
references: 10905580
references: Am J Pathol. 2005 Mar;166(3):721-8
references: 15743784
references: Hepatology. 2005 Jun;41(6):1329-38
references: 15880426
references: Hepatology. 2008 Feb;47(2):737-45
references: 18098322
references: Curr Mol Med. 2009 Feb;9(1):45-51
references: 19199941
references: Gastroenterology. 2003 Jun;124(7):1915-25
references: 12806624
references: Rocz Akad Med Bialymst. 2005;50:142-7
references: 16358954
references: Hepatology. 2007 Oct;46(4):1146-54
references: 17661372
references: Nature. 1998 Jan 1;391(6662):79-82
references: 9422508
references: N Engl J Med. 2005 Sep 22;353(12):1261-73
references: 16177252
references: Nature. 1998 Jan 1;391(6662):82-6
references: 9422509
references: Gastroenterology. 2003 May;124(5):1265-76
references: 12730867
references: Hepatology. 2001 Mar;33(3):530-6
references: 11230731
references: FEBS Lett. 2001 Jul 13;501(1):24-30
references: 11457450
references: Shock. 2005 May;23(5):393-9
references: 15834303
references: Nature. 2000 Jan 6;403(6765):103-8
references: 10638762
references: Cell. 1995 Dec 1;83(5):803-12
references: 8521497
references: Pathology. 2002 Jun;34(3):250-6
references: 12109786
references: J Exp Med. 2001 Apr 2;193(7):827-38
references: 11283155
references: Gastroenterology. 1979 Jun;76(6):1326-32
references: 437429
references: Hepatology. 2003 Nov;38(5):1250-7
references: 14578864
references: Inflamm Bowel Dis. 2011 Feb;17(2):680-1
references: 20848495
references: Lab Invest. 2003 Nov;83(11):1657-67
references: 14615419
references: Gastroenterology. 2001 Feb;120(2):460-9
references: 11159886
references: Gut. 2006 Sep;55(9):1341-9
references: 16905700